US FDA grants marketing approval of octreotide (Mycapssa) capsules for maintenance therapy of adults with acromegaly

Approval is for the treatment of patients who have responded to and tolerated treatment with octreotide or lanreotide andwas based on 9-month Phase III Chiasma Optimal trial (n=56) which met primary (proportion patients who maintained their biochemical response at end of trial).


Biospace Inc.